The few CRF1 antagonists that show oral bioavailability were tested with either peripheral injection of CRF [34] or mainly in the context of icv CRF-induced behavioral outcomes such as increased locomotion, addiction, depression and anxiety [10], [22], [24]. The gene discussed is CRHR1; the disease is depressive symptom measurement.